Methenamine hippurate
Reading File
Finding Sources
Searching PubMed
"methenamine hippurate" AND "urinary tract infections"
Searching the Web
methenamine hippurate FDA label dosing warnings UTI prophylaxis
Reading File
Reading File
Reading Article
PMID: 39955521
Methenamine hippurate (brand example: Hiprex) is a non-antibiotic urinary antiseptic used to prevent recurrent urinary tract infections (UTIs). It is not meant to treat an active UTI, kidney infection, fever, or sepsis.
- How it works: In acidic urine, it breaks down to formaldehyde, which suppresses bacterial growth in the bladder.
- Usual adult preventive dose: 1 g by mouth twice daily. Follow the prescribed regimen rather than self-starting it.
- Best use: Long-term suppression or prevention after an existing UTI has been treated and cleared. The FDA label specifies recurrent UTI prophylaxis or suppression.
- Urine acidity matters: Alkalinizing agents can reduce effectiveness. The label advises avoiding alkalinizing foods/medicines when relevant and monitoring with urine cultures. Do not add high-dose vitamin C or other acidifiers unless a clinician recommends it.
- Do not use / seek prescriber advice first with renal insufficiency, severe liver impairment, severe dehydration, or if taking a sulfonamide antibiotic such as trimethoprim-sulfamethoxazole, because of crystalluria risk.
- Possible adverse effects: nausea, upset stomach, rash, and bladder irritation such as painful/frequent urination. Blood in urine or severe urinary pain warrants medical review.
Evidence supports it as an antibiotic-sparing option for recurrent uncomplicated UTIs in adult women: a 2025 systematic review found it non-inferior to antibiotic prophylaxis for symptomatic recurrence, though further trials are still needed. See the systematic review.
What monitoring is needed during long-term use?
Reading File
Finding Sources
Searching PubMed
"methenamine hippurate" AND monitoring
Searching the Web
methenamine hippurate long term monitoring renal liver function urine culture guidelines
For long-term methenamine hippurate prophylaxis, monitoring is mainly for effectiveness, urinary conditions, kidney/liver safety, and adverse effects.
| What to monitor | Practical approach |
|---|---|
| Clinical benefit | Record breakthrough UTI symptoms, frequency, antibiotic courses, and tolerability. NICE advises review at about 6 months after starting, then at least annually if continuing. |
| Urine cultures | Obtain a urine culture for symptomatic breakthrough episodes, ideally before antibiotics. The product label recommends periodic/repeated cultures to assess whether suppression is working. |
| Renal function | Check baseline creatinine/eGFR, and repeat periodically, particularly in older adults, known kidney disease, dehydration risk, or if renal function may change. It should not be used in renal insufficiency. |
| Liver function | Baseline liver tests are sensible if there is liver disease or risk of hepatic impairment; reassess if symptoms or clinical concern arise. Severe hepatic impairment is a contraindication. |
| Urine pH / medication review | The drug needs acidic urine to work. Review for alkalinising products, especially potassium or sodium citrate UTI sachets, bicarbonate, and some antacids. Routine pH testing is not universally required, but it can be considered if recurrent UTIs continue despite adherence. |
| Adverse effects | Ask about dysuria, urinary frequency, bladder pain, nausea, rash, and especially haematuria. Evaluate promptly if these occur. |
| Drug interactions | Recheck medicines at every review. Avoid concomitant sulfonamides because of crystalluria/precipitate risk. |
There is no universally mandated fixed laboratory interval for everyone. A reasonable clinician-led plan is baseline kidney function, with repeat testing based on age, eGFR, comorbidities, and changes in health status, rather than frequent routine testing in a low-risk person with stable results.
The DailyMed prescribing information specifically calls for repeated urine cultures, notes greater activity in acidic urine, and lists renal insufficiency, severe hepatic insufficiency, severe dehydration, and sulfonamide co-use as important safety issues. NICE supports a 6-month then annual review for recurrent-UTI prophylaxis.
This is a shared conversation. Sign in to Orris to start your own chat.